# Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement

> **NCT00284050** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 151 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Ranibizumab 0.3 mg
- **DRUG:** Ranibizumab 0.5 mg
- **DRUG:** Sham injection

## Key facts

- **NCT ID:** NCT00284050
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2011-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00284050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00284050, "Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00284050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*